Societe Generale Reiterates “Buy” Rating for AstraZeneca plc (AZN)
AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating reaffirmed by Societe Generale in a note issued to investors on Thursday.
A number of other research firms have also recently issued reports on AZN. Morgan Stanley restated an “overweight” rating and set a GBX 5,600 ($75.50) target price on shares of AstraZeneca plc in a research note on Friday, June 23rd. UBS AG set a GBX 5,150 ($69.44) target price on shares of AstraZeneca plc and gave the stock a “neutral” rating in a research note on Tuesday, June 27th. Shore Capital restated a “hold” rating on shares of AstraZeneca plc in a research note on Wednesday, June 21st. Kepler Capital Markets restated a “buy” rating and set a GBX 5,500 ($74.15) target price on shares of AstraZeneca plc in a research note on Monday, June 5th. Finally, Liberum Capital restated a “buy” rating and set a GBX 5,500 ($74.15) target price on shares of AstraZeneca plc in a research note on Monday, June 5th. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and nine have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of GBX 5,041.09 ($67.97).
Shares of AstraZeneca plc (LON:AZN) traded up 3.01% on Thursday, hitting GBX 4912.00. 3,343,608 shares of the stock were exchanged. The firm’s market capitalization is GBX 62.19 billion. The company has a 50-day moving average price of GBX 4,574.46 and a 200-day moving average price of GBX 4,884.61. AstraZeneca plc has a one year low of GBX 3,996.00 and a one year high of GBX 5,520.00.
TRADEMARK VIOLATION WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/09/23/societe-generale-reiterates-buy-rating-for-astrazeneca-plc-azn.html.
In other AstraZeneca plc news, insider Nazneen Rahman bought 39 shares of AstraZeneca plc stock in a transaction on Thursday, July 27th. The shares were purchased at an average cost of GBX 4,370 ($58.92) per share, with a total value of £1,704.30 ($2,297.83).
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.